EPCAM and lung cancer: Exploring the addition of for example biotinylated Spycatcher‐recombinant VAR2CSA malaria protein [27, 28] to biotinylated EpCAM blood samples of cancer patients in which a relatively low number of CTC are detected targeting EpCAM such as nonsmall cell lung cancer, ovarium, pancreas, and colorectal cancer [29, 30] will show whether or not broadening of the target antigens and improving the capture efficiency of low target antigens will improve the enrichment of tumor cells in the blood.